Devanshi Seth

Prof. Devanshi Seth

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
QAQuentin M. Anstee
Quentin M. Anstee
DSDevanshi Seth
Devanshi Seth
CDChristopher P. Day
Christopher P. Day

14 June 2011 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
DSDevanshi Seth
Devanshi Seth
PHPaul S Haber
Paul S Haber
WSWing‐Kin Syn
Wing‐Kin Syn
ADAnna Mae Diehl
Anna Mae Diehl
CDChristopher P Day
Christopher P Day

27 August 2020 in Hepatology
Verified
Journal Article
Closed access
PDF file
TSTae‐Hwi Schwantes‐An
Tae‐Hwi Schwantes‐An
RDRebecca Darlay
Rebecca Darlay
PMPhilippe Mathurin
Philippe Mathurin
SMSteven Masson
Steven Masson
SLSuthat Liangpunsakul
Suthat Liangpunsakul
FCfor the GenomALC Consortium
for the GenomALC Consortium

14 October 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
JWJohn B. Whitfield
John B. Whitfield
TSTae-Hwi Schwantes-An
Tae-Hwi Schwantes-An
RDRebecca Darlay
Rebecca Darlay
GAGuruprasad Aithal
Guruprasad Aithal
SAStephen R. Atkinson
Stephen R. Atkinson
DSDevanshi Seth
Devanshi Seth

1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
DSDevanshi Seth
Devanshi Seth
ADAlastair Duly
Alastair Duly
PKPaul C Kuo
Paul C Kuo
GMGeoff McCaughan
Geoff McCaughan
PHPaul S Haber
Paul S Haber
AIM: To investigate over-expression of Osteopontin (OPN) pathway expression and mechanisms of action in human alcoholic liver disease (ALD), in vivo and in vitro acute alcohol models. METHODS: OPN pathway was evaluated in livers from patients with progressive stages of human ALD and serum from drinkers with and without liver cirrhosis. In vitro stellate LX2 cells exposed to acute alcohol and in vivo in acute alcoholic steatosis mouse models were also investigated for OPN pathway expression and function. WT and OPN-/- mice were administered an acute dose of alcohol and extent of liver injury was examined by histopathology and liver biochemistry after 16-24 h. The causative role of OPN was studied in OPN knockout animals and in vitro in stellate LX2 cells, utilizing siRNA, aptamer and neutralizing antibodies to block OPN and OPN pathway. OPN pathway expression and downstream functional consequences were measured for signaling by Western blotting, plasmin activation by spectrophotometric assays and cell migration by confocal imaging and quantitation. RESULTS: OPN expression positively correlated with disease severity in patients with progressive stages of ALD. In vivo, associated with alcoholic steatosis, a single dose of acute alcohol significantly increased hepatic OPN mRNA and protein, and a cleaved OPN form in a dose dependent manner. OPN mRNA and secreted OPN also increased in parallel with activation of LX2 stellate cells within 4 h of a single dose of alcohol. Expression of OPN receptors, αvβ3-integrin and CD44, increased in human ALD, and in vivo and in vitro with alcohol administration. This was accompanied by downstream phosphorylation of Akt and Erk, increased mRNA expression of several fibrogenesis, fibrinolysis and extracellular matrix pathway genes, plasmin activation and hepatic stellate cell (HSC) migration. Inhibition of OPN and OPN-receptor mediated signaling partially inhibited alcohol-induced HSC activation, plasmin activity and cell migration. CONCLUSION: OPN is a key mediator of the alcohol-induced effects on hepatic stellate cell functions and liver fibrogenesis.

31 August 2020 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
JWJohn B. Whitfield
John B. Whitfield
SMSteven Masson
Steven Masson
SLSuthat Liangpunsakul
Suthat Liangpunsakul
SMSebastian Mueller
Sebastian Mueller
GAGuruprasad Aithal
Guruprasad Aithal
FCfor the GenomALC Consortium
for the GenomALC Consortium
INTRODUCTION: Sustained high alcohol intake is necessary but not sufficient to produce alcohol-related cirrhosis. Identification of risk factors, apart from lifetime alcohol exposure, would assist in discovery of mechanisms and prediction of risk. METHODS: We conducted a multicenter case-control study (GenomALC) comparing 1,293 cases (with alcohol-related cirrhosis, 75.6% male) and 754 controls (with equivalent alcohol exposure but no evidence of liver disease, 73.6% male). Information confirming or excluding cirrhosis, and on alcohol intake and other potential risk factors, was obtained from clinical records and by interview. Case-control differences in risk factors discovered in the GenomALC participants were validated using similar data from 407 cases and 6,573 controls from UK Biobank. RESULTS: The GenomALC case and control groups reported similar lifetime alcohol intake (1,374 vs 1,412 kg). Cases had a higher prevalence of diabetes (20.5% (262/1,288) vs 6.5% (48/734), P = 2.27 × 10−18) and higher premorbid body mass index (26.37 ± 0.16 kg/m2) than controls (24.44 ± 0.18 kg/m2, P = 5.77 × 10−15). Controls were significantly more likely to have been wine drinkers, coffee drinkers, smokers, and cannabis users than cases. Cases reported a higher proportion of parents who died of liver disease than controls (odds ratio 2.25 95% confidence interval 1.55–3.26). Data from UK Biobank confirmed these findings for diabetes, body mass index, proportion of alcohol as wine, and coffee consumption. DISCUSSION: If these relationships are causal, measures such as weight loss, intensive treatment of diabetes or prediabetic states, and coffee consumption should reduce the risk of alcohol-related cirrhosis.